Table 2.
Recommended therapies and their duration depending on the viral genotype
| GT1a | GT1b | GT2 | GT3 | GT4 | GT5 | GT6 | |
|---|---|---|---|---|---|---|---|
| OBV/PTV/r + DSV + RBV | 12–24 weeks | ||||||
| OBV/PTV/r + DSV | 8–12 weeks | ||||||
| OBV/PTV/r ± RBV | 12–24 weeks | ||||||
| ASV + DCV | 24 weeks | ||||||
| SOF/LDV ± RBV | 8–24 weeks | 8–24 weeks | 12–24 weeks | 12–24 weeks | 12–24 weeks | ||
| SOF + PegIFNα + RBV | 12 weeks | 12 weeks | 12 weeks | 12 weeks | |||
| SOF + RBV | 12–24 weeks | 24 weeks | 24 weeks | 24 weeks | 24 weeks | ||
| SOF + DCV + RBV | 24 weeks | 24 weeks | |||||
| SOF/VEL ± RBV | 12 weeks | 12 weeks | 12 weeks | 12 weeks | 12 weeks | 12 weeks | 12 weeks |
| GZR/EBR ± RBV | 12–16 weeks | 12 weeks | 12–16 weeks | ||||
| PegIFNα + RBV* | 48 weeks | 48 weeks | 24 weeks | 24 weeks | 48 weeks |
+ – combined therapy with drugs available as separate preparations
/ – combined therapy with drugs available as one combined preparation
± – addition of RBV depending on indications; details are provided in the text
*
Only recommended in children